Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:18 PM ET 10-Q
Financial Results Atrium Therapeutics, Inc. RNA

Atrium Therapeutics Q3 2026 Results: Net Loss of $4.27M, Loss Widens

Atrium Therapeutics reported a net loss of $41.1 million for the nine months ended September 30, 2026, compared to $20.4 million in the prior year period, driven by a significant increase in general and administrative expenses following its spin-off. The company ended the quarter with $232.1 million in cash, cash equivalents, and short-term investments, bolstered by a $313.4 million transfer from its former parent company.

Key figure
Net loss $4.27M
4:18 PM ET 8-K
Financial Results U S Global Investors Inc GROW

U S Global Investors Financial Results

U.S. Global Investors reported its first quarter fiscal 2027 results, achieving 18% revenue growth to $2.7 million and returning to operating profitability. The company saw a 14% year-over-year increase in average assets under management to $1.6 billion, driven largely by a 45% surge in gold and precious metals strategies.

Term
Q1 2027

“Gold miners continued to draw investor interest during the quarter, and that showed up in our asset levels. Average assets in our gold strategies are up more than 45% from a year ago. We believe disciplined, actively managed exposure to high-quality miners remains an important part of a diversified portfolio, and we’re pleased that more investors appear to agree.”

Frank Holmes, CEO and Chief Investment Officer

“Defense is no longer defined just by aircraft and ships. It’s increasingly being reshaped by artificial intelligence (AI), autonomous systems and cybersecurity. As governments around the world direct more spending toward national security, we believe WAR, our actively managed Smart Beta 2.0 ETF, gives investors targeted exposure to the companies driving that transformation.”

Frank Holmes, CEO and Chief Investment Officer
4:18 PM ET 8-K
Stock Buyback MediaAlpha, Inc. MAX

MediaAlpha Announces $16M Stock Buyback

MediaAlpha repurchased 1,130,000 shares of its Class A common stock from an affiliate of White Mountains Insurance Group in a private transaction for approximately $16.0 million. The shares were purchased at $14.15 per share, representing a 5.5% discount to the previous day's closing price, and will be canceled and retired.

Value
$16M
Counterparty
White Mountains Insurance Group, Ltd.
4:18 PM ET 10-Q
Financial Results MultiSensor AI Holdings, Inc. MSAI

MultiSensor AI Holdings Q3 2026 Results: Net Loss of $1.95M, Loss Widens

MultiSensor AI Holdings reported a net loss of $1.95 million for the quarter ended September 30, 2026, a slight increase from the $1.68 million loss in the prior year period. While nine-month revenue grew to $4.81 million from $4.16 million, the company continues to experience operating losses and negative cash flow from operations as it expands its SaaS capabilities and condition intelligence platform.

Key figure
Net loss $1.95M
4:18 PM ET 8-K
Financial Results ProMIS Neurosciences Inc. PMN

ProMIS Neurosciences Financial Results

ProMIS Neurosciences reported Q3 2026 financial results, ending the period with $44.1 million in cash which is expected to fund operations through 2027. The company reaffirmed that topline data from its Phase 1b PRECISE-AD trial of PMN310 in Alzheimer’s disease remains on track for the first quarter of 2027.

Term
Q3 2026

“The third quarter of 2026 has been productive for ProMIS, following encouraging interim data from our Phase 1b PRECISE-AD trial in Alzheimer’s disease (AD). Based on data generated to date, we continue to believe PMN310 offers a differentiated approach by selectively targeting the most toxic and destructive form of amyloid-beta, the oligomers.”

Neil Warma, President and Chief Executive Officer

“With PRECISE-AD closing out its final stage of patient visits, we look forward to reporting topline data in the first quarter of 2027, which will include safety, biomarker and clinical efficacy measures.”

Neil Warma, President and Chief Executive Officer
4:18 PM ET Form 4
Insider Selling Vertex, Inc. VERX

Vertex CAO Ryan J. Leib Sells $121K of Stock

Ryan J. Leib, CAO, sold 6,963 shares of Vertex, Inc. at $17.39 a share, worth $121K in total on Nov 9, 2026. Shares held after the trade: 810 (-89.6%).

Value
$121K
Shares
6,963
Price
$17.39
Role
CAO
Holding change
-89.6%
Trade date
Nov 9, 2026
4:18 PM ET 10-Q
Financial Results Alumis Inc. ALMS

Alumis Q3 2026 Results: Net Loss of $94.9M, Loss Narrows

Alumis Inc. reported total assets of $488.7 million as of September 30, 2026, supported by a significant increase in marketable securities following its IPO. The company is focused on the development of envudeucitinib (envu) for plaque psoriasis, with plans to submit a New Drug Application by the end of 2026.

Key figure
Net loss $94.9M
4:18 PM ET 8-K
Financial Results Park Dental Partners, Inc. PARK

Park Dental Partners Financial Results

Park Dental Partners reported third quarter 2026 revenue of $64.9 million, a 6% increase year-over-year driven by reimbursement trends and acquisitions. Net income rose 36.1% to $1.7 million, although diluted EPS decreased to $0.27 compared to $0.72 in the prior-year period. The company also highlighted the completion of the Village Family transaction, expanding its network into a fourth state.

Term
Q3 2026

“Third-quarter revenue increased 6%, supported by same-practice growth, an expanding affiliated doctor base and contributions from recently acquired practices. We have made meaningful progress adding clinical capacity and strengthening our platform, and our focus now is converting that capacity and revenue growth into improved productivity and stronger earnings performance.”

Pete Swenson, Chief Executive Officer and Chair of the Board of Directors

“The completion of the Village Family transaction represents an important step in our growth strategy and extends our affiliated practice network into a fourth state. We remain focused on disciplined integration, supporting our affiliated practices and executing against the opportunities already within our business.”

Pete Swenson, Chief Executive Officer and Chair of the Board of Directors
4:18 PM ET Form 4
Insider Selling Loews Corp L

Loews Insider James S. Tisch Sells $27.6M of Stock

James S. Tisch sold 249,921 shares of Loews Corp at $110.07 to $111.25 a share (average $110.46) in 4 transactions, worth $27.6M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 2,809,389 (-0.9%).

Value
$27.6M
Shares
249,921
Average price
$110.46
Holding change
-0.9%
Trade date
Nov 9, 2026 to Nov 10, 2026
4:18 PM ET 10-Q
Financial Results Carlyle Private Equity Partners Fund, L.P.

Carlyle Private Equity Partners Fund Q3 2026 Results: Net Income $13.1M

Carlyle Private Equity Partners Fund, L.P. reported total assets of $477.3 million as of September 30, 2026, a significant increase from $59.0 million at the end of 2025. The fund's investment portfolio grew to a fair value of $280.4 million, supported by substantial cash and cash equivalents of $194.2 million.

Key figure
Net income $13.1M
4:18 PM ET 8-K
Financial Results Prokidney Corp. PROK

Prokidney Financial Results

ProKidney Corp. reported third quarter 2026 financial results, ending the period with $141.9 million in cash and marketable securities to fund operations into mid-2027. The company remains on track to deliver pivotal Phase 3 PROACT 1 surrogate endpoint topline results in Q2 2027. R&D expenses increased to $40.8 million, driven by clinical study and manufacturing costs for the ongoing rilparencel program.

Term
Q3 2026

“The third quarter marked continued progress for ProKidney, with PROACT 1 advancing toward full enrollment and our pivotal eGFR slope topline readout remaining on track for the second quarter of 2027. The data presented at Kidney Week further build the mechanistic and clinical evidence supporting rilparencel and provide a more cohesive picture of how it may stabilize kidney function. Together, these advances reinforce our confidence as we approach this important Phase 3 readout and continue our mission to transform the treatment of advanced CKD.”

Bruce Culleton, M.D., CEO of ProKidney
4:18 PM ET Form 4
Insider Selling Wyndham Hotels & Resorts, Inc. WH

Wyndham Hotels & Resorts Chief Commercial Officer Scott R. Strickland Sells $957K of Stock

Scott R. Strickland, Chief Commercial Officer, sold 12,000 shares of Wyndham Hotels & Resorts, Inc. at $79.77 a share, worth $957K in total on Nov 9, 2026. Shares held after the trade: 29,490 (-28.9%).

Value
$957K
Shares
12,000
Price
$79.77
Role
Chief Commercial Officer
Holding change
-28.9%
Trade date
Nov 9, 2026
4:18 PM ET Form 4
Insider Selling Boeing Co BA

Boeing EVP, Pres. & CEO, BGS David Christopher Raymond Sells $524K of Stock

David Christopher Raymond, EVP, Pres. & CEO, BGS, sold 2,994 shares of Boeing Co at $174.91 a share, worth $524K in total on Nov 9, 2026. Shares held after the trade: 38,456 (-7.2%).

Value
$524K
Shares
2,994
Price
$174.91
Role
EVP, Pres. & CEO, BGS
Holding change
-7.2%
Trade date
Nov 9, 2026
4:18 PM ET Form 4
Insider Selling Frontier Group Holdings, Inc. ULCC

Frontier Group Holdings EVP, Legal & Corporate Affairs Howard Diamond Sells $297K of Stock

Howard Diamond, EVP, Legal & Corporate Affairs, sold 35,401 shares of Frontier Group Holdings, Inc. at $8.40 a share, worth $297K in total on Nov 9, 2026. Shares held after the trade: 133,126 (-21.0%).

Value
$297K
Shares
35,401
Price
$8.40
Role
EVP, Legal & Corporate Affairs
Holding change
-21.0%
Trade date
Nov 9, 2026
4:17 PM ET Form 4
Insider Selling Frontier Group Holdings, Inc. ULCC

Frontier Group Holdings SVP, Human Resources Steve Schuller Sells $41.8K of Stock

Steve Schuller, SVP, Human Resources, sold 5,000 shares of Frontier Group Holdings, Inc. at $8.35 a share, worth $41.8K in total on Nov 10, 2026. Shares held after the trade: 89,324 (-5.3%).

Value
$41.8K
Shares
5,000
Price
$8.35
Role
SVP, Human Resources
Holding change
-5.3%
Trade date
Nov 10, 2026
4:17 PM ET 8-K
Investor Presentation American Homes 4 Rent, L.P. AMH

American Homes 4 Rent Investor Presentation

American Homes 4 Rent (AMH) has published a formal investor presentation titled 'Investor Highlights–November 2026' to its website and filed it with the SEC. The presentation provides strategic updates on the company's single-family rental portfolio, development program, and 2026 financial guidance. The filing is a standard Regulation FD disclosure intended to provide current highlights to analysts and investors.

4:17 PM ET 8-K
Leadership Change GrabAGun Digital Holdings Inc. PEW

GrabAGun Digital Holdings Leadership Change

GrabAGun Digital Holdings Inc. appointed W. Bryan Hill to its Board of Directors and its Audit and M&A Committees, effective November 9, 2026. Mr. Hill is a veteran public-company executive who previously served as CFO of Alkami Technology and RealPage. He will receive an initial grant of restricted stock units valued at $150,000 as part of his non-employee director compensation.

4:17 PM ET Form 4
Insider Selling Encore Capital Group Inc ECPG

Encore Capital Group Insider Laura Olle Sells $1.18M of Stock

Laura Olle sold 10,493 shares of Encore Capital Group Inc at $112.75 to $113.14 a share (average $112.93) in 2 transactions, worth $1.18M in total on Nov 9, 2026. Shares held after the trade: 26,675 (-17.3%).

Value
$1.18M
Shares
10,493
Average price
$112.93
Holding change
-17.3%
Trade date
Nov 9, 2026
4:17 PM ET 8-K
Financial Results Dragonfly Energy Holdings Corp. DFLI

Dragonfly Energy Holdings Financial Results

Dragonfly Energy reported Q3 2026 net sales of $12.2 million, down 23.8% year-over-year due to softness in the RV market, though heavy-duty trucking revenue more than doubled sequentially. The company completed the acquisition of the Dakota Lithium brand during the quarter and expects to reach approximately breakeven Adjusted EBITDA in Q4 2026.

Term
Q3 2026

“Third quarter heavy-duty trucking revenue more than doubled sequentially to $1.3 million, in line with our August outlook, driven by expanding commercial fleet adoption. For the first time, we received orders from fleets moving directly into commercial deployment without a pilot program, reflecting the credibility we have established through years of field validation.”

Dr. Denis Phares, Chief Executive Officer
4:17 PM ET 10-Q
Financial Results Prairie Operating Co. PROP

Prairie Operating Q3 2026 Results: Net Loss of $48.9M

Prairie Operating Co. reported a significant increase in revenues to $311.8 million for the nine months ended September 30, 2026, compared to $158.6 million in the prior year. However, the company incurred a net loss of $92.6 million for the period, driven largely by a $266.2 million loss on derivatives and increased operating expenses.

Key figure
Net loss $48.9M
4:17 PM ET 8-K
Financial Results Electra Therapeutics, Inc. ETRA

Electra Therapeutics Financial Results

Electra Therapeutics reported third quarter 2026 financial results and provided updates on its SIRP-targeting portfolio, including the advancement of ipsoprubart in a global registrational program for sHLH. The company recently completed a $350 million IPO to fund its clinical pipeline, with several data readouts and enrollment milestones expected throughout 2027.

“Our recent IPO positions Electra to build on our first-mover advantage in SIRP-targeted precision immune cell depletion. Our deep expertise in SIRP biology and proprietary library of SIRP-targeting antibodies enable us to selectively address distinct pathogenic immune cell populations, creating therapeutic optionality across immune-mediated diseases and cancer.”

Kathy Dong, PharmD, MBA, President and Chief Executive Officer
4:17 PM ET 8-K
Financial Results Cytosorbents Corp CTSO

Cytosorbents Financial Results

CytoSorbents reported Q3 2026 financial results, highlighting the achievement of operating cash flow breakeven (excluding restructuring payments). Revenue grew 3% to $9.7 million, while operating loss improved by 59% to $1.2 million due to disciplined cost management and improved gross margins.

Term
Q3 2026

“The third quarter marked an important financial milestone for CytoSorbents as we achieved our goal of operating cash flow breakeven, excluding restructuring-related payments. This achievement reflects a year of disciplined execution and meaningful improvements in our underlying business.”

Dr. Phillip Chan, Chief Executive Officer
4:17 PM ET 10-Q
Financial Results Fulcrum Therapeutics, Inc. FULC

Fulcrum Therapeutics Q3 2026 Results: Net Loss of $10.9M, Loss Narrows

Fulcrum Therapeutics is currently pursuing a merger with Slate Medicines, Inc. while undergoing significant restructuring, including the cessation of clinical development for pociredir and a workforce reduction. The company reported a net loss of $56.0 million for the nine months ended September 30, 2026, and currently has no product candidates in active clinical development.

Key figure
Net loss $10.9M
4:17 PM ET 8-K
Shareholder Meeting Amcor plc AMCR

Amcor Shareholder Meeting

Amcor plc held its 2026 Annual General Meeting where shareholders re-elected ten directors and ratified PricewaterhouseCoopers LLP as the independent auditor. Shareholders also approved executive compensation, the renewal of the company's share repurchase authorization, and the adoption of the 2026 Omnibus Management Share Plan.

4:17 PM ET Form 4
Insider Selling Frontier Group Holdings, Inc. ULCC

Frontier Group Holdings SVP & CFO Mark Christopher Mitchell Sells $332K of Stock

Mark Christopher Mitchell, SVP & CFO, sold 40,798 shares of Frontier Group Holdings, Inc. at $8.15 a share, worth $332K in total on Nov 11, 2026. Shares held after the trade: 66,584 (-38.0%).

Value
$332K
Shares
40,798
Price
$8.15
Role
SVP & CFO
Holding change
-38.0%
Trade date
Nov 11, 2026
4:17 PM ET 8-K
Financial Results System1, Inc. SST

System1 Financial Results

System1, Inc. reported its financial results for the third quarter ended September 30, 2026, disclosing revenue of $25.95 million. The company recorded a significant net loss of $51.28 million for the quarter, impacted by a $63.6 million impairment charge on goodwill and other long-lived assets.

Term
Q3 2026
4:17 PM ET 10-Q
Financial Results Longeveron Inc. LGVN

Longeveron Q3 2026 Results: Net Loss of $6.13M, Loss Narrows

For the nine months ended September 30, 2026, Longeveron Inc. reported a net loss of $16.9 million, a slight improvement from the $17.3 million loss in the prior year period. Total revenues decreased slightly to $0.8 million, while the company strengthened its cash position to $7.2 million through private placements and warrant exercises.

Key figure
Net loss $6.13M
4:17 PM ET 10-Q
Financial Results Birchtech Corp. BCHT

Birchtech Q3 2026 Results: Net Loss of $275K

Birchtech Corp. reported a net loss of $4.6 million for the nine months ended September 30, 2026, compared to a $2.4 million loss in the prior year period, despite a 23% increase in product revenue. The company significantly strengthened its balance sheet during the period, ending with $10.8 million in cash following a common stock issuance that raised approximately $14.2 million in net proceeds.

Key figure
Net loss $275K
4:17 PM ET 10-K
Financial Results Franklin Covey Co FC

Franklin Covey FY 2026 Results: Net Income $4.92M, Up 60.5% YoY

Franklin Covey Co. reported fiscal 2026 consolidated revenue of $261.5 million, a 2% decrease from the prior year, while net income improved to $4.9 million. Despite lower revenues in the Enterprise Division due to macroeconomic uncertainties and geopolitical tensions, Adjusted EBITDA increased slightly to $28.9 million, supported by restructuring activities and cost reduction efforts.

Key figure
Net income $4.92M · +60.5% YoY
4:17 PM ET 10-Q
Financial Results Holistic Asset Finance Group Co., Ltd. HAFG

Holistic Asset Finance Group Co Q3 2026 Results: Turns Profitable, Net Income $7.32K

Holistic Asset Finance Group Co., Ltd. reported a significant increase in revenue to $4.94 million for the nine months ended September 30, 2026, compared to $1.69 million in the prior year. The company achieved a small net income of $2,436 for the period, recovering from a net loss of $36,331 in 2025, primarily driven by its export trading and marketing services operations.

Key figure
Net income $7.32K

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.